¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"RNA (New York, N.Y.)"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • RNA, ribosomal
    ¸®º¸¼Ø RNA, rRNA
  • RNA, transfer
    Àü´ÞRNA, tRNA
  • RNA,, messenger
    Àü·É RNA, mRNA
  • RNA-dependent DNA polymerase
    RNA-ÀÇÁ¸ DNA ÁßÇÕÈ¿¼Ò
  • RNA=£¾ribonucleic acid
    ¸®º¸ÇÙ»ê.
  • hybridization, DNA-RNA
    DNA-RNA ¦Áö¿ì±â, DNA-RNA ºÎÇÕÈ­(~ݬùêûù)
  • immunogen RNA
    ¸é¿ª¿ø¼º RNA.
  • positive strand RNA
    ¾ç¼º°¡´Ú RNA
  • pseudoknot RNA structure
    ¸ÅµìÇü RNA ±¸Á¶
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • messenger RNA
    Àü·É RNA
  • messenger ribonucleic acid =m RNA
    Àü·É RNA.
  • messenger ribonucleic acid =m RNA
    Àü·É ¸®º¸ÇÙ»ê.
  • messenger ribonucleic acid= m RNA
    Àü·É¸®º¸ÇÙ»ê(îîç©¡­ú·ß«).
  • negative strand RNA
    À½¼º°¡´Ú RNA
  • positive strand RNA
    ¾ç¼º°¡´Ú RNA
  • pseudoknot RNA structure
    ¸ÅµìÇü RNA ±¸Á¶
  • ribonucleic acid =RNA
    ¸®º¸ÇÙ»ê (¡­ú·ß«).
  • ribosomal RNA
    ¸®º¸¼Ø¸®º¸ÇÙ»ê(¡­ú·ß«).
  • rna oncogenic virus
    RNA(¸®º¸ÇÙ»ê)¹ß¾Ï¼º ¹ÙÀÌ·¯½º(Û¡äßàõ¡­)
  • subgenomic RNA
    ¾ÆÁö³ð RNA
  • subgenomic m-RNA
    ¾ÆÁö³ð mRNA
  • transfer RNA
    ÀüÀÌ RNA
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • heterogeneous nuclear RNA
    ÀÌÁú(ì¶òõ) ÇÙ(ú·)RNA
  • immediate early RNA
    ÃÖÁ¶±â(õÌðÄÑ¢) RNA
  • infectious RNA
    °¨¿°¼º(Êïæøàõ) RNA
  • initiator transfer RNA
    °³½Ã(ËÒã·) Àü´Þ(îîÓ¹)RNA
  • isoacceptor transfer RNA
    µ¿Á¾¼ö³³Ã¼(ÔÒðúáôÒ¡ô÷) ÀüÀÌ(ï®ì¹)RNA
  • messenger RNA
    Àü·É(îîÖµ)RNA
  • messenger RNA hypothesis
    Àü·É(îîÖµ)RNA¼³(àã)
  • methionyl transfer RNA
    ¸ÞƼ¿À´Ñ Àü´Þ(îîÓ¹) RNA
  • methyl-poor transfer RNA
    °ú(Íû)¸ÞÆ¿ Àü´Þ(îîÓ¹)RNA
  • mic RNA
    ¹Í RNA
  • modulator transfer RNA
    Á¤Á¶ÀÚ(ïÚðàí­) Àü´Þ(îîÓ¹) RNA
  • monocistronic messenger RNA
    ´Ü(Ó¤)½Ã½ºÆ®·Ð Àü´Þ(îîÓ¹) RNA
  • nascent RNA
    ½Å»ý(ãæßæ) RNA
  • pathogenic RNA
    º´¿ø¼º(Ü»ê«àõ) RNA
  • polycistronic messenger RNA
    ´Ù(Òý)½Ã½ºÆ®·Ð Àü·É(îîÖµ) RNA
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HARS histidyl-RNA synthetase
poly-IC, poly-I:C copolymer of polyinosinic and polycytidylic acids; synthetic RNA polymer
RNA radionuclide angiography; Registered Nurse Anesthetist; ribonucleic acid; rough, noncapsulated, avir...
U-RNA uridylic acid ribonucleic acid
NB New-Born
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
D RNA defective RNA
HCV RNA Hepatitis C virus RNA
hn-RNA Heteronuclear RNA
I-RNA Immune RNA
poly(A)+ RNA Polyadenylated RNA
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
New World leishmaniasis A grave disease caused by Leishmania braziliensis braziliensis, endemic in southern Mexico and Central and South America, except for the equatorial region of Chile; the organism does not invade the viscera, and the disease is limited to the skin and mucous membranes, the lesions resembling the sores of cutaneous leishmaniasis caused by L. Mexicana or L. Tropica; the chancrous sores heal after a time, but some months or years later, fungating and eroding forms of ulceration may appear on the tongue and buccal or nasal mucosa; many variants of the disease exist, marked by differences in distribution, vector, epidemiology, and pathology, which suggest that it may in fact be caused by a number of closely related aetiological agents.
See: espundia.
Synonym: American leishmaniasis, leishmaniasis americana, nasopharyngeal leishmaniasis, New World leishmaniasis.
(05 Mar 2000)
new yellow enzyme The d-amino-acid oxidase found in yeast, a flavoenzyme, which contains FAD as coenzyme instead of FMN as does NADPH dehydrogenase; so-called to distinguish it from Warburg's old yellow enzyme.
Compare: amino acid oxidases.
(05 Mar 2000)
new zealand A group of islands in the South Pacific Ocean. New Zealand flax.
<botany> A myrtaceous shrub (Leptospermum scoparium) of new Zealand and Australia, the leaves of which are used as a substitute for tea.
Source: Websters Dictionary
(01 Mar 1998)
New Zealand mice Inbred strains of mice, either black (NZB) or white (NZW), unique among strains used in experimental immunology because of their proclivity to spontaneous immunologic abnormalities and disorders including systemic lupus erythematosus similar to that found in humans.
(05 Mar 2000)
investigational new drug Status given an experimental drug after the FDA approves an application for testing it in people.
(09 Oct 1997)
investigational new drug application An application that must be submitted to a regulatory agency (the FDA in the united states) before a drug can be studied in humans. This application includes results of previous experiments; how, where, and by whom the new studies will be conducted; the chemical structure of the compound; how it is thought to work in the body; any toxic effects found in animal studies; and how the compound is manufactured.
(12 Dec 1998)
acceptor RNA rNA
antisense RNA <molecular biology> A complementary RNA sequence that binds to (and thus blocks the transcription of) a naturally-occuring (sense) messenger RNA molecule.
These proteins can be used to selectively turn off production of certain proteins or block viral genetic instructions, by marking them for destruction by cellular enzymes, in order to prevent the building of new virus or the infection of new cells.
(09 Oct 1997)
bacteriophage T3 RNA polymerase <enzyme> Used for the rapid generation of strand-specific RNA molecules that can be used for the identification of genes in hybridization experiments
Registry number: EC 2.7.7.-
Synonym: t3 RNA polymerase
(26 Jun 1999)
cap II RNA(nucleoside-2'-)methyltransferase <enzyme> Converts cap i-terminated mRNA to cap II-terminated mRNA
Registry number: EC 2.1.1.-
Synonym: cap II methylase
(26 Jun 1999)
cap I RNA (nucleoside-2'-)methyltransferase <enzyme> Converts cap 0-terminated mRNA to cap i-terminated mRNA
Registry number: EC 2.1.1.-
Synonym: cap I methylase
(26 Jun 1999)
p68 RNA helicase <enzyme> An RNA helicase isolated from uv-induced tumours in mice; amino acid sequence has been determined
Registry number: EC 2.7.7.-
Synonym: dead box helicase p68
(26 Jun 1999)
masked messenger RNA <molecular biology> Long lived and stable mRNA found originally in the oocytes of echinoderms and constituting a store of maternal information for protein synthesis that is unmasked (derepressed) during the early stages of morphogenesis.
In these early stages the rate of cell division is so rapid that transcription from the embryonic genome cannot occur. Undoubtedly not restricted to oocytes and the term can be applied to any mRNA which is present in inactive form.
(18 Nov 1997)
ribosomal RNA <molecular biology> A nucleic acid found in all living cells. Plays a role in transferring information from DNA to the protein-forming system of the cell.
(16 Dec 1997)
messenger-like RNA An ill-defined form of RNA, of high molecular weight, that never leaves the nucleus and is thought to be the precursor of messenger RNA.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • new
    »õ·Î¿î
  • new-made
    °íÃĸ¸µç
  • NEW
    net economic welfare
  • New Amsterdam
    ´º¾Ï½ºÅ׸£´ã(³×´ú¶õµå·É ´ç½ÃÀÇ New York CityÀÇ À̸§)
  • New Britain
    ´ººê¸®Åæ(³²ÅÂÆò¾ç BismarckÁ¦µµ ÁßÀÇ ÃÖ´ëÀÇ ¼¶,ÁÖ¿ä µµ½ÃRabaul)
  • New Caledonia
    ¿À½ºÆ®·¹Àϸ®¾Æ µ¿ÂÊÀÇ ¼¶
  • New Christian
    MARRANO
  • New Critic
    ½ÅºñÆò°¡
  • New Criticism
    ½ÅºñÆò
  • New Deal
    ´ºµôÁ¤Ã¥(Roosevelt ¹Ì±¹ ´ëÅë·ÉÀÌ 1933³â¿¡ Á¦Ã¢ÇÑ °æÁ¦ ºÎÈï°ú »çȸ º¸ÀåÀÇ ÁõÁø Á¤Ã¥)
  • New Delhi
    ´ºµ¨¸®(Àεµ °øÈ­±¹ÀÇ ¼öµµ
  • New Economic Policy
    ½Å°æÁ¦Á¤Ã¥,³×ÇÁ
  • New England
    ÀÌÁö¹æÀÌ ¿µ±¹ÇؾȰú ºñ½ÁÇÏ´ÙÇØ¼­ Captain John Smith°¢ ¸í¸í)´ºÀ×±Û·£µå¹Ì±¹ºÏµ¿ºÎÀÇ ¿©¼¸ÁÖConnecticut;Massachusetts;Rhode Island;Vermont;New Hampshire;Maine)
  • New Englander
    ´ºÀ×±Û·£µå »ç¶÷
  • New English Bible
    ½Å ¿µ¿ª¼º¼­(½Å¾à 1961³â,½Å±¸¾àÇÕº» 1970³â¿¡ °£Çà
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á